Sugi Predict

Sugi Predict / Compounds / SCHEMBL14658665

SCHEMBL14658665

SCHEMBL14658665

O=C(O)c1cnc(N2CCCCC2)cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ LMNA P02545 1/20 0.45
▸ ALOX12 P18054 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ KMO O15229 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ CNR2 P34972 2/20 0.40
▸ KDM4E B2RXH2 3/20 0.39
▸ POLB P06746 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30855580 1.00 MAPT (0.45) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL25666898 0.98 MAPT (0.44) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL29546455 0.88 HRH3 (0.49) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL5041190 0.86 HRH3 (0.50) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL24315987 0.84 PRKCQ (0.43) RAB9AL3MBTL1HRH3HDAC3HDAC2
SCHEMBL28630760 0.83 HDAC3 (0.46) ALDH1A1SMN1; SMN2RAB9AKDM4EL3MBTL1
SCHEMBL29907656 0.83 KMO (0.60) MAPTALDH1A1LMNAKMOSMN1; SMN2
SCHEMBL322646 0.83 KMO (0.60) MAPTALDH1A1LMNAKMOSMN1; SMN2
SCHEMBL877503 0.83 HRH3 (0.43) KMOHRH3HCAR2
SCHEMBL10241318 0.83 HDAC3 (0.52) ALDH1A1KMOKDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4071145-B1 JAK INHIBITOR COMPOUND AND USE THEREOF LU LIANG (CN) 2025-01-08 — — EP disclosed
EP-3932919-B1 JAK INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECH CO LTD (CN) 2024-06-26 — — EP disclosed
US-20230201165-A1 JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-06-29 — — US disclosed
US-20230201165-A1 JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-06-29 — — US disclosed
US-20230192711-A1 JAK INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-06-22 — — US disclosed
US-20230192711-A1 JAK INHIBITOR COMPOUND AND USE THEREOF HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-06-22 — — US disclosed
EP-4186907-A1 JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA Henan Medinno Pharmaceutical Technology Co., Ltd. (CN) 2023-05-31 — — EP disclosed
US-20220388992-A1 JAK INHIBITOR COMPOUND AND USE THEREOF LU LIANG (CN) 2022-12-08 — — US disclosed
US-20220388992-A1 JAK INHIBITOR COMPOUND AND USE THEREOF LU LIANG (CN) 2022-12-08 — — US disclosed
EP-4071145-A1 JAK INHIBITOR COMPOUND AND USE THEREOF Lu, Liang (CN) 2022-10-12 — — EP disclosed
EP-2736907-B1 INDAZOLES PFIZER LTD (GB) 2015-10-07 — — EP disclosed
US-8895544-B2 Indazoles PFIZER LIMITED (GB) 2014-11-25 — — US disclosed
WO-2014146490-A1 CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-09-25 — — WO disclosed
EP-2736907-A1 INDAZOLES Pfizer Limited (GB) 2014-06-04 — — EP disclosed
CN-103717599-A Indazoles PFIZER 2014-04-09 — — CN disclosed
US-20140024634-A1 INDAZOLES PFIZER LIMITED (GB) 2014-01-23 — — US disclosed
US-8575336-B2 Indazoles PFIZER LIMITED (GB) 2013-11-05 — — US disclosed
CN-101522644-B Pyrazine-2-carboxamide derivatives as cb2 receptor modulators HOFFMANN LA ROCHE 2013-04-24 — — CN disclosed
US-20130029968-A1 INDAZOLES PFIZER LIMITED (GB) 2013-01-31 — — US disclosed
WO-2013014567-A1 INDAZOLES PFIZER LIMITED (GB) 2013-01-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029968-A1 INDAZOLES CYP11B2, CYP11B1, IL33 MAPT 1270/4885ALDH1A1 175/4885LMNA 3679/4885
US-20220388992-A1 JAK INHIBITOR COMPOUND AND USE THEREOF JAK2, JAK1, JAK3 MAPT 407/4885ALDH1A1 2410/4885LMNA 4671/4885
US-20230192711-A1 JAK INHIBITOR COMPOUND AND USE THEREOF JAK2, JAK1, JAK3 MAPT 414/4885ALDH1A1 2919/4885LMNA 4633/4885
US-20230201165-A1 JAK INHIBITOR COMPOUND FOR TREATING SEVERE PNEUMONIA JAK1, JAK2, JAK3 MAPT 365/4885ALDH1A1 4146/4885LMNA 4633/4885
US-20140024634-A1 INDAZOLES JAK1, JAK3, JAK2 MAPT 515/4885ALDH1A1 1947/4885LMNA 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.